A Cohort Study on the Integrated Management of Chronic Kidney Disease

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorHuashan Hospital

About this trial

The study will leverage the established multi-stage cohort resources at Huashan Hospital, covering the entire spectrum from early-stage CKD to dialysis, including a comorbidity real-world database, a prospective CKD patient cohort, and a maintenance hemodialysis patient real-world cohort. It will also collaborate with the Shanghai Fifth People's Hospital (community-based CKD cohort, n\>2,000) and the Jing'an District Central Hospital (end-stage renal disease cohort, n\>400) as external validation platforms. Using epidemiological and big data-driven approaches, the study aims to elucidate the mechanisms underlying disease progression and complications, construct intelligent intervention models, and validate their performance in the external cohorts, ultimately facilitating the optimization and broader application of comprehensive CKD management strategies.

Eligibility criteria

Qualifiers

Patients who have documented outpatient or inpatient records at Huashan Hospital, Shanghai Fifth People's Hospital, or Jing'an District Central Hospital during the period from September 2018 to September 2025.

Aged 18-90 years.

Diagnosed with one or more of the 48 pre-specified common chronic diseases according to ICD-10 codes.

Patients diagnosed with end-stage renal disease (CKD stage 5) and receiving long-term maintenance hemodialysis, with a dialysis vintage of at least 3 months.

Disqualifiers

Patients whose dialysis-related data and key clinical variables (e.g., creatinine, proteinuria, and other outcome-related indicators) are missing or severely illogical, and which are deemed unusable for research purposes upon evaluation.

Patients with poor compliance during dialysis, or those receiving palliative dialysis.

Other conditions that the investigators consider inappropriate.

Patients who have experienced acute kidney injury within 3 months prior to enrollment, or who are in an acute stress state such as acute infection, myocardial infarction, or other acute conditions at the time of screening.

Trial design

Treatments tested in this trial

  • Retrospective data collection
  • Prospective data collection
  • External validation

Treatment groups

4,029 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Huashan Hospital

Lead sponsor

Jingan District Central Hospital of Shanghai (Jingan Branch of Huashan Hospital Affiliated to Fudan University)

Collaborator

Fudan University Affiliated Shanghai Fifth People's Hospital Hospital

Collaborator